Business Wire

Jubilant DraxImage Signs Term Sheet with Cyclopharm for Exclusive License to Market Technegas in the United States


Jubilant DraxImage Inc. (“DraxImage”) and Cyclopharm Limited (“CYC”) are pleased to announce the signing of a term sheet, subject to satisfactory due diligence and execution of the Definitive Agreement and other necessary approvals, providing DraxImage an exclusive license to market and distribute Technegas in the United States. DraxImage will assist CYC with the development and financing of the phase III clinical trials for Technegas, and any other steps required to file for and obtain USFDA approval.

This Smart News Release features multimedia. View the full release here:

DraxImage President Martyn Coombs stated, “Jubilant DraxImage is excited about this opportunity to participate with Cyclopharm in the clinical development and potential US market introduction of this innovative nuclear medicine product. The execution of this Term Sheet demonstrates DraxImage’s commitment to invest in and grow the sustainability of ventilation/perfusion imaging in the US and our continued passion to bring innovative products that enable physicians to deliver high quality diagnostics to their patients”.

Cyclopharm CEO James McBrayer stated that “Cyclopharm is thrilled with the opportunities this transaction represents. DraxImage is the USA market leader for nuclear medicine lung imaging. We are confident that the synergies that exist between our organizations will ensure faster acceptance of our proprietary technology.”

About Jubilant DraxImage

Jubilant DraxImage Inc., a subsidiary of Jubilant Life Sciences, develops, manufactures and commercializes radiopharmaceuticals used for the diagnosis and treatment of disease. The company is dedicated to nuclear medicine and serves customers and through them patients, globally, with high quality and reliable products and services. The company is the market leader in North America for I-131 products (diagnosis and treatment of thyroid disorder and cancer), MAA (lung perfusion imaging), DTPA (renal imaging) and MDP (bone imaging), and also markets other products such as Sestamibi (myocardial perfusion imaging) and Gluceptate (brain and renal imaging). The company has a strong development pipeline of new products, notably a Rubidium-82 Generator (PET Cardiology).

About Cyclopharm Limited

Cyclopharm is a radiopharmaceutical company servicing the global medical community. The Company’s mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas (for lung imaging).

About Technegas

The Technegas technology is a structured ultra-fine dispersion of radioactive labeled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,700oC. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for the superior diagnosis of pulmonary emboli (blood clots in the lungs).

Contact information

Jubilant DraxImage
Ms Suzanne Bissonnette, 1-888-633-5343
Director, Marketing
Cyclopharm Limited
Mr James McBrayer, +61 295 41 04 11
CEO, Managing Director & Company Secretary

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

The Saga Foundation Announces Its Plan to Create a Non-Anonymous, Reserve-Backed Digital Currency22.3.2018 13:00Pressemelding

The Saga Foundation ( announces today its mission to create Saga (SGA), the first non-anonymous blockchain-based digital currency. The currency is designed with a tamed volatility mechanism. These characteristics can set the ground for the currency to become a store of value and a medium of exchange. Saga is designed to address legitimate concerns expressed by policy makers, regulators and market participants regarding cryptocurrencies; mainly their anonymity, lack of underlying value and high volatility. Saga holders must satisfy full KYC (Know Your Customer) qualification and AML (Anti Money Laundering) requirements under Swiss law. With such disclosures, Saga resolves concerns about participant accountability, an issue that is generally raised regarding cryptographic currencies. Saga aims to promote a low-volatility environment, combining the virtues of blockchain technologies with algorithmic representations of financial tools. For this reason, Saga is backed by a variable Celebrates the Launch of Their Spring Collection & the Zendaya Edit with a 90s Throwback Block Party!22.3.2018 12:48Pressemelding

This evening, international etailer,, celebrated the launch of their newest Spring collection at an exclusive launch party in Los Angeles at The Dream Hollywood for media, influencers, and friends of the brand. This press release features multimedia. View the full release here: Celebrates the Launch of their Spring Collection & the Zendaya Edit with a 90s Throwback Block Party! Taking note from the product aesthetic, the event served as the ultimate 90s nostalgia trip with bright and bold décor from neon signs to giant boom boxes and life-size cassette tapes. Throughout the night, guests engaged in various activations including 90s dance lessons, cocktail making, cooking lessons, firework displays and interactive arcade games. Attendees also enjoyed 90s-inspired catering including retro treats Bubble Tape and Candy Necklaces, as well as Slush Puppies and Sunny D cocktails. Surprise musical guests, Snoop Dog

Synchronoss Renews Agreement to Power Verizon Cloud22.3.2018 12:00Pressemelding

Synchronoss Technologies, Inc. (NASDAQ:SNCR), a global leader and innovator of cloud, messaging, digital and IoT products, today announced that it has renewed its existing agreement with Verizon to power Verizon’s Cloud solution for its wireless customers for an additional five years. Synchronoss’ Personal Cloud Platform and solutions will continue to provide Verizon customers with simple, secure access to all personal content, including photos, videos, messages and more, from any device. “We’re delighted to be renewing our contract with one of our longest-serving and most valued customers,” said Glenn Lurie, President & CEO at Synchronoss. “The fully agnostic and secure Synchronoss Personal Cloud solution maintains high levels of customer trust in operators by meeting their mutual need for additional storage and capacity head on.” Synchronoss is the world’s leading provider of operator cloud solutions, with more than 160 million people currently using the Synchronoss Personal Cloud so

Takeda Announces Publication of Final Data from ICLUSIG® (ponatinib) Pivotal Phase 2 PACE Trial in Blood22.3.2018 12:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that final data from the pivotal Phase 2 PACE clinical trial of ICLUSIG (ponatinib) in refractory chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) were published in Blood . The manuscript is available online today and will be included in a future print edition of Blood. The final five-year results support ICLUSIG as an effective treatment option for patients with chronic-phase CML (CP-CML) whose prior therapies have failed. ICLUSIG, a tyrosine kinase inhibitor (TKI) with potent activity against native and mutant forms of BCR-ABL1 (an abnormal tyrosine kinase that is expressed in CML and Ph+ ALL), received full approval from the U.S. Food and Drug Administration in 2016. ICLUSIG is indicated for the treatment of adult patients with CML or Ph+ ALL for whom no other TKI is indicated, including those with T315I-positive CML or T315I-positive Ph+ ALL. ICLUSIG is not ind

German Company Develops New Solution for Monetizing News Content22.3.2018 11:41Pressemelding

MulTra GmbH has created an innovative solution to monetize digital content for newspaper publishers while simultaneously paying consumers for reading the news through their Pumped App. Pumped claims to be the first platform which pays people for reading news content while guaranteeing 100% ad revenue to publishers at no-sign up cost. “We developed the Pumped App working with feedback from major international publishers to address the challenge of monetizing news content,” said MulTra GmbH CEO Onik Mia. “By using the Pumped App, consumers are paid in the Ethereum-based MulTra Token (MTT) to read publisher content and earn cryptocurrency.” MulTra GmbH is a member of the Enterprise Ethereum Alliance. The Pumped App is platform independent and any publisher, regardless of size, can participate in the Pumped ecosystem for free. Media industry leaders and blockchain experts recently gathered at the Soho House Berlin to discuss how Pumped can increase monetization of content independent of th

Liquidnet Rolls Out Virtual High Touch Solution for Best Execution Analysis22.3.2018 11:00Pressemelding

Liquidnet, the global institutional trading network today announced the launch of Best Ex Replay, the newest addition to the Liquidnet Virtual High Touch suite powered by data and analytics from OTAS Technologies. Best Ex Replay™ enables traders to recall precise market conditions to explain the context of execution decisions, investigate orders that experienced exceptional market conditions, and to help their firm meet regulatory reporting requirements such as MiFID II. It also enables traders to provide detailed execution feedback to Portfolio Managers. “What we’ve heard from our global Membership is that every minute that goes into manual, administrative tasks such as compliance requests and best execution analysis—while valuable—is time that comes at the expense of alpha generation,” said Natasha Shamis, Global Head of Product. “Traders need to spend their time on achieving best execution, not proving it. That’s what Best Ex Replay is for.” When a trader uses Best Ex Replay to rese